Lucid Capital Markets analyst Christopher Liu initiates coverage on NextCure Inc. (NASDAQ: NXTC) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage